Puma Biotechnology (PBYI) Projected to Post Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect Puma Biotechnology to post earnings of $0.02 per share and revenue of $44.55 million for the quarter. Puma Biotechnology has set its FY 2025 guidance at EPS and its Q1 2025 guidance at EPS.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.29. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The firm had revenue of $59.10 million for the quarter, compared to analyst estimates of $52.50 million. On average, analysts expect Puma Biotechnology to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Puma Biotechnology Stock Down 0.3 %

Shares of PBYI traded down $0.01 during mid-day trading on Friday, hitting $3.00. 164,147 shares of the company's stock were exchanged, compared to its average volume of 441,898. The stock has a market cap of $148.83 million, a price-to-earnings ratio of 6.25 and a beta of 1.34. The firm has a fifty day moving average of $3.11 and a two-hundred day moving average of $3.03. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. Puma Biotechnology has a twelve month low of $2.23 and a twelve month high of $5.26.

Analyst Ratings Changes

PBYI has been the subject of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price target on shares of Puma Biotechnology in a research report on Friday, February 28th. StockNews.com raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Friday.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.